The Distinction of Clinicopathological Characteristics, Treatment Strategy and Outcome in Colorectal Cancer Patients With Synchronous vs. Metachronous Bone Metastasis

Chenxi Ma, Xu Guan, Ran Wei, Song Wang, Jichuan Quan, Zhixun Zhao, Haipeng Chen, Zheng Liu, Zheng Jiang, Xishan WangFrontiers in Oncology 2020 · DOI

Introduction

Bone metastasis (BM) in colorectal cancer (CRC) is a relatively rare clinical occurrence, affecting approximately 3–10% of patients. Due to its low prevalence compared to liver or lung metastases, standardized clinical guidelines for its management are sparse. A critical factor in understanding the progression of BM is the timing of its diagnosis. This study investigates whether patients who present with BM at the time of initial CRC diagnosis (Synchronous BM) differ significantly in clinical profile and treatment response from those who develop BM during follow-up (Metachronous BM).

Methodology and Patient Cohort

Researchers conducted a retrospective analysis of patients treated at the Chinese National Cancer Center between 2008 and 2017. Synchronous BM (SBM) was defined as metastasis detected within three months of the primary CRC diagnosis, while Metachronous BM (MBM) was defined as detection after three months.

Figure 1: Flowchart of the analytical cohort selection and exclusion criteria.

The final analysis included 201 patients: 63 in the SBM group and 138 in the MBM group. The study evaluated various clinicopathological factors, including tumor location, grade, AJCC stage, and treatment modalities such as primary tumor resection, chemotherapy, targeted therapy, bisphosphonates, and radiotherapy.

Clinical Characteristics: Different Origins and Spread

The study revealed significant differences in how SBM and MBM manifest:

  • Primary Tumor Location: MBM was more frequently associated with rectal cancer (60.9%) compared to SBM (41.3%).
  • Extent of Metastasis: MBM patients were significantly more likely to present with multiple bone lesions (63.0%) than SBM patients (7.9%), suggesting a more systemic and widespread progression over time.

Survival Outcomes: The 11-Month Paradox

Despite the differences in clinical presentation and the more widespread nature of MBM, the median Cancer-Specific Survival (CSS) after BM diagnosis was identical for both groups: 11 months.

Figure 3: Kaplan-Meier curves showing the probability of specific survival for SBM and MBM groups. Both groups exhibit a median survival of 11 months (p = 0.556).

While the overall median survival was the same, the patient's history played a role in MBM outcomes. Patients whose primary CRC was initially diagnosed at an early stage (AJCC Stage I) had a significantly longer survival (28 months) compared to those diagnosed at an advanced stage (Stage IV, 8 months).

Treatment Implications and Prognostic Factors

The study identified distinct treatment sensitivities between the two groups, providing actionable insights for clinical decision-making:

  • SBM Management: Survival in the SBM group was independently predicted by the number of bone lesions, KPS scores, primary tumor resection, and the use of bisphosphonates. SBM patients derived a clear survival benefit from bone-strengthening medication.
  • MBM Management: For the MBM group, positive CA199 levels, lack of primary tumor resection, and lack of radiotherapy were independent predictors of poor survival. Radiotherapy appeared more beneficial for MBM patients.
  • Shared Benefits: Primary tumor resection was associated with improved survival in both groups, emphasizing the value of local control even in metastatic disease. Interestingly, targeted therapy did not show a significant survival benefit in this specific cohort.

Conclusion

CRC patients with SBM and MBM represent distinct clinical subgroups. While they share a similar overall prognosis of 11 months, their clinicopathological characteristics and optimal treatment strategies differ. SBM patients may benefit more from bisphosphonates, while radiotherapy is a key survival factor for MBM patients. These findings underscore the need for "distinct considerations" in the clinical management of bone metastasis based on the timing of its emergence.

Summary updated

Abstract

<b>Background:</b> The impact of the timing of bone metastasis (BM) diagnosis on colorectal cancer (CRC) patients is unclear. Our study aimed to explore the differences in clinicopathological characteristics, treatments and prognosis between synchronous BM (SBM) and metachronous BM (MBM) from CRC. <b>Methods:</b> We retrospectively investigated clinical data of CRC patients with SBM or MBM from 2008 to 2017 at Chinese National Cancer Center. Cancer specific survival (CSS) after BM diagnosis was estimated using the Kaplan-Meier method. The multivariable COX regression model identified the prognostic factors of CSS. <b>Results:</b> Finally, 63 CRC patients with SBM and 138 CRC patients with MBM were identified. Compared to SBM from CRC, MBM significantly was more involving multiple bone lesions (63.0 vs. 7.9%; <i>p</i> < 0.001), and more frequently originated from rectal cancer (60.9 vs. 41.3%; <i>p</i> = 0.033). The therapeutic strategies in SBM and MBM group were contrasted including systemic treatment, bisphosphonates, radiotherapy and metastasectomy for BM. 85.5% of patients in MBM group and 25.4% of patients in SBM group underwent primary tumor resection at initial diagnosis (<i>p</i> < 0.001). The median CSS was 11 months in both SBM and MBM group (<i>p</i> = 0.556), yet MBM patients developed from CRC in early AJCC stage presented obviously longer survival than those from advanced stage. Furthermore, patients could have improved CSS from primary tumor resection while there might be no survival benefit from targeted therapy in both SBM and MBM groups. Bisphosphonates was associated with a better CSS for patients with SBM, while radiotherapy for BM was related to a better CSS for patients with MBM. <b>Conclusion:</b> The CRC patients in SBM and MBM group represented different clinicopathological characteristics and treatment modalities, which affected the prognosis in different ways. Distinct consideration for CRC patients with SBM and MBM in clinical decision making is required.
BibTeX
@inproceedings{ma2020distinction,
  author = {Chenxi Ma and Xu Guan and Ran Wei and Song Wang and Jichuan Quan and Zhixun Zhao and Haipeng Chen and Zheng Liu and Zheng Jiang and Xishan Wang},
  title = {{The Distinction of Clinicopathological Characteristics, Treatment Strategy and Outcome in Colorectal Cancer Patients With Synchronous vs. Metachronous Bone Metastasis}},
  booktitle = {Frontiers in Oncology},
  year = {2020},
  doi = {10.3389/fonc.2020.00974},
}
Figure